iPLATO Wins SBRI Funding to Reduce GP Workload

20th June  2017

iPLATO Healthcare has won Phase 1 funding from the Small Business Research Initiative (SBRI) to reduce GP workload through its innovative digital health solution. The funding will be used to develop and trial its proprietary Intelligent Care Navigation solution within Primary Care.

Using Intelligent Care Navigation (ICN), iPLATO Healthcare sign-posts users of its myGPTM  app to alternatives to a traditional GP appointment, where appropriate. With general practice in the UK under increasing demand, solutions to help avoid unnecessary GP appointments that could be handled by alternate providers like pharmacies, local services, and extended hours hubs. ICN also enables a surgery to more effectively sign-post a patient to other clinicians within the surgery, like nurses, healthcare assistants, and pharmacists.

Digital Health Age wrote:

iPlato was awarded the contract based on its launch of the new smartphone app, myGP last year. iPlato’s platform has around 15 million NHS patients connected to over 1,650 GP practices across the UK.

The company hopes that its approach to patient care navigation will reduce the need and pressure on GP appointments and help patients gain better access to instant medical care and advice.

Tobias Alpsten, CEO, iPLATO comments: “We are all incredibly excited about the investment from SBRI, allowing us to introduce a smarter and seamless process to care navigation. Transforming access to primary care offers obvious advantages to patients and their carers, but it also benefits commissioners and tax payers by reducing pressure on the healthcare system. We believe an intuitive and robust approach to empowering the patient through quality information and alternative pathways can make a real difference in improving access to healthcare, ensuring patients are seen promptly by the most appropriate healthcare professional as well as supporting those living with long-term health conditions.”

Read the full article on Digital Health Age.